Gocatamig

Phase 2Small molecule

Gocatamig is one of 26 small molecule programs targeting Small Cell Lung Cancer Extensive Stage. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Small Cell Lung Cancer Extensive StageRecruiting

Advanced CancersActive, not recruiting

Small Cell Lung Cancer Extensive StagePreclinical

Recruiting

Advanced CancersPhase 2

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Advanced Cancers

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Approved

9 2

Keytruda

Merck & Co.

Phase 2

6 3

Taxol

Teva

Phase 2

3 4

Camptosar

Pfizer

Phase 2

3 5

Adriamycin

Pfizer

Phase 2

2 6

Tecentriq

Roche

Phase 2

2 7

Abraxane

Bristol-Myers Squibb

Phase 2

2 8

Lynparza

AstraZeneca

Phase 2

1 9

Paraplatin

AAvyxa

Phase 2

3 10

Ativan

BBausch Health Americas, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Active, not recruiting

Advanced Cancers

NCT04471727

Q2 2029

PreclinicalRecruiting

Small Cell Lung Cancer

NCT06780137

Q4 2030

PreclinicalRecruiting

Small Cell Lung Cancer Extensive Stage

NCT07227597

Clinical

Trials by Indication[1]

Advanced Cancers1 trial

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT04471727·232 enrolled

Small Cell Lung Cancer1 trial

A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06780137·327 enrolled

Small Cell Lung Cancer Extensive Stage1 trial

A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07227597·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Gocatamig. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gocatamig compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gocatamig. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

Gocatamig

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2029

Q4 2030

Trials by Indication[1]

Advanced Cancers1 trial

Small Cell Lung Cancer1 trial

Small Cell Lung Cancer Extensive Stage1 trial

References

Drug Info

Quick Facts

Related News